Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to test the safety of bevacizumab when given in combination
with gemcitabine and oxaliplatin and to see what effects (good and bad) this combination has
on patients with cancer of bile duct or gallbladder. Bevacizumab has been shown to slow or
stop cell growth in tumors by decreasing the blood supply to the tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute Genentech, Inc. Sanofi